#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Antikoagulační terapie dabigatranem vs rivaroxabanem u seniorů ve věku nad 65 let: porovnání dat „head to head“


Authors: Martin Polák
Authors‘ workplace: JIP interních oborů Interního oddělení Oblastní nemocnice Příbram, a. s.
Published in: Vnitř Lék 2017; 63(4): 289-291
Category: Actualities


Sources

1. Čihák R, Haman L, Táborský M et al. Doporučené postupy ESC 2016 pro léčbu fibrilace síní formulované ve spolupráci s EACTS. Cor et vasa 2016; 58(6): 728–771.

2. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation dveloped in Collaboration with EACTS. Europace 2016; 18(11): 1609–1678.

3. Graham DJ, Reichman ME, Wernecke M et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med 2016; 176(11): 1662–1671.

4. Schaefer JK, McBane RD, Wysokinski WE. How to Choose Appropriate Direct Oral Anticoagulant for Patient with Nonvalvular Atrial Fibrillation. Ann Hematom 2016; 95(3): 437–449.

5. Shenasa M, Camm JA. Management of Atrial Fibrillation. Oxford University Press: Oxford 2015. ISBN 978–0-19–968631–5.

Labels
Diabetology Endocrinology Internal medicine
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#